Enhanced Inhibition of Tumorigenesis Using Combinations of MiRNA-Targeted Therapeutics

Overview

Journal Front Pharmacol

Date 2019 Jun 4

PMID 31156429

Citations 37

Authors

Svetlana Miroshnichenko

Olga Patutina

Affiliations

Soon will be listed here.

Abstract

The search for effective strategies to inhibit tumorigenesis remains one of the most relevant scientific challenges. Among the most promising approaches is the direct modulation of the function of short non-coding RNAs, particularly miRNAs. These molecules are propitious targets for anticancer therapy, since they perform key regulatory roles in a variety of signaling cascades related to cell proliferation, apoptosis, migration, and invasion. The development of pathological states is often associated with deregulation of miRNA expression. The present review describes in detail the strategies aimed at modulating miRNA activity that invoke antisense oligonucleotide construction, such as small RNA zippers, miRNases (miRNA-targeted artificial ribonucleases), miRNA sponges, miRNA masks, anti-miRNA oligonucleotides, and synthetic miRNA mimics. The broad impact of developed miRNA-based therapeutics on the various events of tumorigenesis is also discussed. Above all, the focus of this review is to evaluate the results of the combined application of different miRNA-based agents and chemotherapeutic drugs for the inhibition of tumor development. Many studies indicate a considerable increase in the efficacy of anticancer therapy as a result of additive or synergistic effects of simultaneously applied therapies. Different drug combinations, such as a cocktail of antisense oligonucleotides or multipotent miRNA sponges directed at several oncogenic microRNAs belonging to the same/different miRNA families, a mixture of anti-miRNA oligonucleotides and cytostatic drugs, and a combination of synthetic miRNA mimics, have a more complex and profound effect on the various events of tumorigenesis as compared with treatment with a single miRNA-based agent or chemotherapeutic drug. These data provide strong evidence that the simultaneous application of several distinct strategies aimed at suppressing different cellular processes linked to tumorigenesis is a promising approach for cancer therapy.

Citing Articles

MicroRNA Significance in Cancer: An Updated Review on Diagnostic, Prognostic, and Therapeutic Perspectives.

Singh V, Sen A, Saini S, Dwivedi S, Agrawal R, Bansal A EJIFCC. 2025; 35(4):265-284.

PMID: 39810890 PMC: 11726331.

Targeting drug resistance in breast cancer: the potential of miRNA and nanotechnology-driven delivery systems.

Verma A, Patel K, Kumar A Nanoscale Adv. 2024; 6(24):6079-6095.

PMID: 39569336 PMC: 11575621. DOI: 10.1039/d4na00660g.

Joint masking and self-supervised strategies for inferring small molecule-miRNA associations.

Zhou Z, Zhuo L, Fu X, Lv J, Zou Q, Qi R Mol Ther Nucleic Acids. 2024; 35(1):102103.

PMID: 38261851 PMC: 10794920. DOI: 10.1016/j.omtn.2023.102103.

A novel therapeutic strategy: the significance of exosomal miRNAs in acute myeloid leukemia.

Salehi A Med Oncol. 2024; 41(2):62.

PMID: 38253748 DOI: 10.1007/s12032-023-02286-1.

Exploring the Relationship between Fusion Genes and MicroRNAs in Cancer.

Panicker S, Chengizkhan G, Gor R, Ramachandran I, Ramalingam S Cells. 2023; 12(20).

PMID: 37887311 PMC: 10605240. DOI: 10.3390/cells12202467.

References

Li H, Xing C, Zhou B, Ye H, Feng J, Wu J . A regulatory circuitry between miR-193a/miR-600 and WT1 enhances leukemogenesis in acute myeloid leukemia. Exp Hematol. 2018; 61:59-68.e5. DOI: 10.1016/j.exphem.2018.02.001. View

Huynh C, Segura M, Gaziel-Sovran A, Menendez S, Darvishian F, Chiriboga L . Efficient in vivo microRNA targeting of liver metastasis. Oncogene. 2010; 30(12):1481-8. DOI: 10.1038/onc.2010.523. View

Wang H, Ren S, Xu Y, Miao W, Huang X, Qu Z . MicroRNA-195 reverses the resistance to temozolomide through targeting cyclin E1 in glioma cells. Anticancer Drugs. 2018; 30(1):81-88. PMC: 6287895. DOI: 10.1097/CAD.0000000000000700. View

Teplyuk N, Uhlmann E, Gabriely G, Volfovsky N, Wang Y, Teng J . Therapeutic potential of targeting microRNA-10b in established intracranial glioblastoma: first steps toward the clinic. EMBO Mol Med. 2016; 8(3):268-87. PMC: 4772951. DOI: 10.15252/emmm.201505495. View

Quintavalle C, Garofalo M, Zanca C, Romano G, Iaboni M, Del Basso De Caro M . miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTPμ. Oncogene. 2011; 31(7):858-68. PMC: 4299860. DOI: 10.1038/onc.2011.280. View

Li H, Wu Q, Li T, Liu C, Xue L, Ding J . The miR-17-92 cluster as a potential biomarker for the early diagnosis of gastric cancer: evidence and literature review. Oncotarget. 2017; 8(28):45060-45071. PMC: 5542167. DOI: 10.18632/oncotarget.15023. View

Cheng H, Xue J, Yang S, Chen Y, Wang Y, Zhu Y . Co-targeting of IGF1R/mTOR pathway by miR-497 and miR-99a impairs hepatocellular carcinoma development. Oncotarget. 2017; 8(29):47984-47997. PMC: 5564620. DOI: 10.18632/oncotarget.18207. View

Niu W, Wu S, Xu Z, Lin J, Zhan R . [Anti-leukemia mechanism of miR-17 and miR-20a silencing mediated by miRNA sponge]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014; 22(4):932-7. DOI: 10.7534/j.issn.1009-2137.2014.04.010. View

Evers M, Toonen L, van Roon-Mom W . Antisense oligonucleotides in therapy for neurodegenerative disorders. Adv Drug Deliv Rev. 2015; 87:90-103. DOI: 10.1016/j.addr.2015.03.008. View

10.

Patel K, Panchal H, Karanwal A, Parekh B, Shah S, Prasad S . Sunitinib in metastatic renal cell carcinoma: Experience from single center study, efficacy and safety. Indian J Cancer. 2016; 53(1):118-22. DOI: 10.4103/0019-509X.180844. View

11.

Xiao W, Lou N, Ruan H, Bao L, Xiong Z, Yuan C . Mir-144-3p Promotes Cell Proliferation, Metastasis, Sunitinib Resistance in Clear Cell Renal Cell Carcinoma by Downregulating ARID1A. Cell Physiol Biochem. 2017; 43(6):2420-2433. DOI: 10.1159/000484395. View

12.

Amponsah P, Fan P, Bauer N, Zhao Z, Gladkich J, Fellenberg J . microRNA-210 overexpression inhibits tumor growth and potentially reverses gemcitabine resistance in pancreatic cancer. Cancer Lett. 2016; 388:107-117. DOI: 10.1016/j.canlet.2016.11.035. View

13.

Li Y, Ping C, Tang J, Zhang W . MicroRNA-455 suppresses non-small cell lung cancer through targeting ZEB1. Cell Biol Int. 2016; 40(6):621-8. DOI: 10.1002/cbin.10584. View

14.

Kim D, Kim K, Seo Y, Yang H, Marcusson E, Son E . Anti-miR delivery strategies to bypass the blood-brain barrier in glioblastoma therapy. Oncotarget. 2016; 7(20):29400-11. PMC: 5045404. DOI: 10.18632/oncotarget.8837. View

15.

Sharma S, Rajendran V, Kulshreshtha R, Ghosh P . Enhanced efficacy of anti-miR-191 delivery through stearylamine liposome formulation for the treatment of breast cancer cells. Int J Pharm. 2017; 530(1-2):387-400. DOI: 10.1016/j.ijpharm.2017.07.079. View

16.

Yu G, Jia B, Cheng Y, Zhou L, Qian B, Liu Z . MicroRNA-429 sensitizes pancreatic cancer cells to gemcitabine through regulation of PDCD4. Am J Transl Res. 2017; 9(11):5048-5055. PMC: 5714789. View

17.

Kim V, Han J, Siomi M . Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol. 2009; 10(2):126-39. DOI: 10.1038/nrm2632. View

18.

Li X, Liang L, Huang L, Cai S . Standard chemotherapy with cetuximab for treatment of colorectal cancer. World J Gastroenterol. 2015; 21(22):7022-35. PMC: 4462745. DOI: 10.3748/wjg.v21.i22.7022. View

19.

Chen X, Peng D, Shen Y, Liu B, Zhou H, Tao H . The potential combinational effect of miR-34a with celecoxib in osteosarcoma. Anticancer Drugs. 2017; 28(8):888-897. DOI: 10.1097/CAD.0000000000000530. View

20.

Rupaimoole R, Calin G, Lopez-Berestein G, Sood A . miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. Cancer Discov. 2016; 6(3):235-46. PMC: 4783232. DOI: 10.1158/2159-8290.CD-15-0893. View